Bocunebart Biosimilar Monoclonal Antibody (PACAP) for Research

Cat No.: GMP-Bios-INN-1106

Anti-ADCYAP1/PACAP therapeutic antibody (Pre-made Bocunebart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Bocunebart (development codes ALD1910/LU AG-09222) is a humanized monoclonal antibody targeting pituitary adenylate cyclase-activating polypeptide (PACAP/ADCYAP1). It is developed by H. Lundbeck for migraine. It is in Phase II clinical development.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1106-1mg 1mg 3090
GMP-Bios-INN-1106-10mg 10mg
GMP-Bios-INN-1106-100mg 100mg
GMP-Bios-INN-1106-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Bocunebart biosimilar, Whole mAb, Anti-ADCYAP1/PACAP Antibody: Anti-ADCYAP1/PACAP-38/Pituitary adenylate cyclase-activating polypeptide/PACAP therapeutic antibody
INN Name Bocunebart
Target ADCYAP1/PACAP
Format Whole mAb
Derivation Humanized
Species Reactivity Human
CH1+2+3 Isotype G1
VD LC Kappa
Highest_Clin_Trial (Jan '20) TBC
Est. Status TBC
100% SI Structure None
99% SI Structure None
95-98% SI Structure None
Year Proposed 2025
Year Recommended na
Companies TBC
Conditions Approved TBC
Conditions Active TBC
Conditions Discontinued TBC
Production na
Development Tech TBC